Gastrobody Therapeutics Limited
16196935
Healthy
No risk factors detected.
Details
Compliance
Next accounts due
21/10/2026
Confirmation statement
Last: 24/11/2025
Due 08/12/2026
Industry
Officers
Persons with Significant Control
Dr Yasunori Watanabe
Japanese · England
Notified 21/01/2025
Dr Ana Rossi
British · England
Notified 21/01/2025
Former PSCs
Dr Mark Raymond Howarth
Ceased 09/07/2026
CompanyRankvs 2522+ SIC 72110 peers58
Show leaderboard
How is this score calculated?
Net worth compared to all companies in the same SIC code with published accounts. Top quartile earns the full 25 points.
Workforce size relative to sector peers from the most recent accounts. A larger team generally signals commercial scale.
Current assets ÷ current liabilities. A ratio above 2× earns full marks; between 1–2× scores partially; below 0.5× scores minimal points.
One point per year of operation since incorporation, capped at 15. Older companies have a proven track record.
Full 15 points when both annual accounts and confirmation statement are filed on time. Points are deducted for each overdue filing.
Maximum score is 100. Deductions apply for insolvency history, outstanding charges, going concern doubt, or disqualified officers.
Key FinancialsYear ending 31/01/2026
Net Worth
£36k
Balance sheet strength
Cash
—
Cash in the bank
Net Current Assets
£36k
Working capital
Current Assets
£36k
Current Liabilities
£0
Balance Sheet
EstimatesDerived
| Year | Current Ratio |
|---|---|
| 2026 | Infinity |
Derived from filed accounts. Not audited figures.